Now, it’s worth noting Stock Advisor's total average return is 1,079% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

The device, called Biolinq Shine, is indicated for people with Type 2 diabetes who don’t depend on insulin. Biolinq says its ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $99.3, a high estimate of $106.00, and a low estimate of $89.00. Marking an ...

ViCentra's Kaleido is "the smallest, thinnest, lightest, most precise insulin patch pump in its class," CEO Tom Arnold said ...

Oura Health makes a pricey smart ring that busy executives, celebrities and others use to track health measures like their ...

Biolinq Shine’s use of a microsensor array mitigates the need for an introducer needle for sensor placement as in traditional ...

In a further comparison using DPP-4i/SU as the reference, the GLP-1 RA/SGLT2i combination therapy had the greatest effect in ...

Qualcomm laid out its AI vision at the Snapdragon Summit — the ecosystem of you will extend our voices in new modalities with ...

The URC returns this weekend with some familiar faces and some new blood on the scene as Munster, Connacht and Ulster aim to ...

GE HealthCare gets downgraded slightly to a hold from my prior buy rating last fall, agreeing with Seeking Alpha's quant ...

For the growing number of children with type 1 diabetes, the daily burden of managing their challenging chronic disease and ...

USBC shifts from med-tech to fintech, focusing on a dollar-backed stablecoin and Bitcoin treasury. Click here to find out why ...